New lung fluid test could sharpen predictions for cancer treatment
NCT ID NCT07331701
Summary
This study aims to learn if analyzing immune cells from a patient's lung fluid, along with a standard tumor marker (PD-L1), can better predict how well someone with advanced lung cancer will respond to treatment. Researchers will collect lung fluid and tumor tissue from 60 patients during their normal care to look for patterns. The goal is to find better ways to forecast treatment outcomes and survival, which could help guide future personalized care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SMG-SNU Boramae Medical Center
Seoul, Dongjak-gu, 07061, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.